APA (7th ed.) Citation

Ku, J. H., Qian, L., Sy, L. S., Ackerson, B. K., Rayens, E., Luo, Y., . . . Modha, P. P. (2026). Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis. Open Forum Infectious Diseases, 13(5), 1. https://doi.org/10.1093/ofid/ofag279

Chicago Style (17th ed.) Citation

Ku, Jennifer H., et al. "Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis." Open Forum Infectious Diseases 13, no. 5 (2026): 1. https://doi.org/10.1093/ofid/ofag279.

MLA (9th ed.) Citation

Ku, Jennifer H., et al. "Real-world Effectiveness of Adjuvanted RSVPreF3 Vaccine in Preventing RSV-associated Lower Respiratory Tract Disease Hospitalization in Adults ≥60 Years of Age: Early Results From a Test-negative Design Analysis." Open Forum Infectious Diseases, vol. 13, no. 5, 2026, p. 1, https://doi.org/10.1093/ofid/ofag279.